Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone scan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,309 result(s) found for: Bone scan. Displaying page 3 of 66.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003177-26 Sponsor Protocol Number: RT2019-13 Start Date*: 2020-02-05
    Sponsor Name:UMCG
    Full Title: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy
    Medical condition: Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014456-29 Sponsor Protocol Number: Cord01 Start Date*: 2009-09-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA
    Medical condition: Advanced chordoma EGFR/Her2Neu positive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039492 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001434-16 Sponsor Protocol Number: 3D_CHB/collacone Start Date*: 2016-03-30
    Sponsor Name:Universitätsmedizin Greifswald, KöR
    Full Title: A method for measuring volume changes of the alveolar ridge during dental implantation using 3D scanning
    Medical condition: alveolar ridge atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10074846 Alveolar bone resorption PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002223-42 Sponsor Protocol Number: A4091061 Start Date*: 2015-10-12
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER ...
    Medical condition: Metastatic Bone Pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) SK (Completed) HU (Completed) RO (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003888-56 Sponsor Protocol Number: 20192022 Start Date*: 2021-01-30
    Sponsor Name:Department of Nephrology, Herlev & Gentofte Hospital, Herlev Hospital
    Full Title: Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10060881 Adynamic bone disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000701-11 Sponsor Protocol Number: CA180227 Start Date*: 2008-11-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer Revised Protocol 03 incorporating A...
    Medical condition: castration-resistant metastatic prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IE (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed) FI (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017649-67 Sponsor Protocol Number: nnisbjl2009 Start Date*: 2010-06-22
    Sponsor Name:The Central Remedial Clinic and The Children's University Hospital
    Full Title: Bone Health in Duchenne Muscular Dystrophy- a case controlled study of Risedronate use
    Medical condition: Bone Health in Duchenne Muscular Dystrophy- a randomised controlled study of Risedronate use
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002738-36 Sponsor Protocol Number: G-0029 Start Date*: 2005-11-08
    Sponsor Name:Cell Genesys Inc
    Full Title: A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve
    Medical condition: Metastatic Hormone-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10036909
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022576-30 Sponsor Protocol Number: BA058-05-003 Start Date*: 2011-02-21
    Sponsor Name:Radius Health, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopau...
    Medical condition: Osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) LT (Completed) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003642-26 Sponsor Protocol Number: 3116001 Start Date*: 2014-12-17
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-204 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): OPEN, NONRANDOMISED, UNCONTROLLED, MULTICENTRE, DOSE ESCALATION, FIRST-IN-MAN STUDY W...
    Medical condition: Metastatic castration resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-001787-36 Sponsor Protocol Number: 1333-GUCG Start Date*: 2015-09-14
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metas...
    Medical condition: Castration resistant prostate cancer patients metastatic to bone.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002898-12 Sponsor Protocol Number: CZOL446K2418 Start Date*: 2008-10-24
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Estudio abierto de re-tratamiento con Aclasta® en pacientes que han presentado recaída de la Enfermedad ósea de Paget y que participaron en los estudios de registro CZOL446K2304 y CZOL446K2305.
    Medical condition: Tratamiento para la Enfermedad ósea de Paget
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033363 Paget's disease of bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002940-26 Sponsor Protocol Number: 212082PCR3011 Start Date*: 2013-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me...
    Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-002416-16 Sponsor Protocol Number: ALLOB-RIF1 Start Date*: 2014-08-04
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Rescue Interbody Fusion
    Medical condition: Failed lumbar fusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021566 10050238 Spinal fusion NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003033-41 Sponsor Protocol Number: 2005040 Start Date*: 2006-03-20
    Sponsor Name:Procter & Gamble Technical Centres Limited
    Full Title: A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomi...
    Medical condition: Osteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. ...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002054-39 Sponsor Protocol Number: ODX-002 Start Date*: 2014-11-10
    Sponsor Name:DexTech Medical AB
    Full Title: A randomized, double-blind, placebo-controlled multi-centre phase II study to evaluate efficacy and tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
    Medical condition: Metastatic Castration Resistant Prostate Cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000097-15 Sponsor Protocol Number: M16-191 Start Date*: 2020-11-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) NL (Completed) AT (Completed) BE (Completed) GR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004545-15 Sponsor Protocol Number: MLAM 2007/01 Start Date*: 2008-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: The Split Dose Study: Split dose Rhenium-188-HEDP regimen in hormone refractory prostate cancer patients with bone metastases; a phase I toxicity study and phase II efficacy study.
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003705-27 Sponsor Protocol Number: MK URO 4 Start Date*: 2007-09-27
    Sponsor Name:AKH Vienna
    Full Title: RANDOMIZED, CONTROLLED BIOMARKER STUDY EVALUATING THE ANTI-ANGIOGENIC ACTIVITY OF SUNITINIB IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS TREATED BY DOCETAXEL
    Medical condition: hormone refraktory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 15:15:17 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA